Fig. 1.
AAT reduces mortality from GvHD. (A) B6D2F1 mice were irradiated with 1,000 centigray (cGy) of total-body irradiation on day −1 and transplanted with 5 × 106 T-cell–depleted BM cells and 2 × 106 CD90+T cells from either syngeneic F1 or allogeneic B6 donors. Each allo-recipient was injected i.p. with either 4 mg hAAT (n = 9) or human albumin (n = 9) for 6 d from day −2 to day +13. Data shown are combined from two similar experiments. Percentage survival after BMT is shown. For ▼ vs. ▲, P < 0.02. (B) B6 mice were given 1,000 cGy of total-body irradiation on day −1 and transplanted with 5 × 106 T-cell–depleted BM cells and 2 × 105 CD8+T cells from either syngeneic B6 or allogeneic C3H.SW donors. Each allo-recipient was injected i.p. with either 2 mg hAAT (n = 17) or human albumin (n = 16) for 6 d from day −2 to day +13 and was monitored for GvHD survival. Data shown are combined from three similar experiments. Percentage survival after BMT is shown. For ▼ vs. ▲, P = 0.029. (C) C3H.SW mice were irradiated as above and transplanted with 4 × 106 T-cell–depleted BM cells and 1 × 106 CD90+T cells from either syngeneic C3H.SW or allogeneic B6 donors. The allo-recipients were injected i.p. with either 2 mg hAAT (n = 12) or human albumin (n = 15) and were monitored for GvHD survival as above. Data shown are combined from two similar experiments. Percentage survival after BMT is shown. For ▼ vs. ▲, P = 0.019.